about
Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab.Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans.Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trialStatistical Issues in Testing Conformance with the Quantitative Imaging Biomarker Alliance (QIBA) Profile Claims.Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imagingDynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters.Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme.Association of internal carotid artery injury with carotid canal fractures in patients with head trauma.Gain in signal-to-noise for first-pass contrast-enhanced abdominal MR angiography at 3 Tesla over standard 1.5 Tesla: prediction with a computer model.Comparison of patient age with MR imaging features of gangliogliomas.Dynamic contrast enhanced-MRI in head and neck cancer patients: variability of the precontrast longitudinal relaxation time (T10)Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter BrainInterreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 Study
P50
Q30891381-1AFA153C-9C3F-460A-A635-1D73242D78D9Q33568752-078C05F7-920B-471A-B6EF-9DE1AB827E41Q35159477-43F18E6A-E1BD-4474-923D-D010001CB4B5Q35815291-D6DA2AA7-B0EF-452F-A424-9754861B35DFQ36797014-E698FBAF-BDB8-4E92-8C8C-01346BA8F978Q37126776-6F7227C4-593A-4C20-BE3F-07EE7FFFFEEBQ44413175-DDE3D53A-4E8B-40E5-A316-AD1221A741C8Q48648329-E9BC88C8-700D-442A-81D1-3B43827CEC5DQ48911681-B074A37A-92C2-4236-9CFA-8F20F826F097Q53476805-32D4D84E-4FEE-4DB1-81DD-A5CD4D322E8FQ55475997-E2E1D00D-1F80-4444-8E10-DB9B4FCF5E93Q57154307-85D467D8-F91C-4C19-AB2C-2608404C097EQ93086225-D6AD2C5A-60B1-4D87-A796-A0B59B7EDD57Q93334530-4F59C7DE-6F8E-4FEC-8E95-E4FB0570FD1A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daniel Barboriak
@ast
Daniel Barboriak
@en
Daniel Barboriak
@es
Daniel Barboriak
@nl
Daniel Barboriak
@sl
type
label
Daniel Barboriak
@ast
Daniel Barboriak
@en
Daniel Barboriak
@es
Daniel Barboriak
@nl
Daniel Barboriak
@sl
prefLabel
Daniel Barboriak
@ast
Daniel Barboriak
@en
Daniel Barboriak
@es
Daniel Barboriak
@nl
Daniel Barboriak
@sl
P1053
M-4414-2015
P106
P108
P21
P31
P3829
P496
0000-0002-2536-6266
P569
2000-01-01T00:00:00Z